Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Daily News

Patients With Schizophrenia Reap Gains From CV Meds After MI

Todd Neale

October 24, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

Shelley Wood

October 02, 2018

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Daily News

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Yael L. Maxwell

April 04, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Daily News

‘High Index of Suspicion’ First Step in Successful Management of SCAD

Michael O'Riordan

February 27, 2018

News Daily News

Compliance With Preventive Drugs After CABG, PCI Found Lacking in Clinical Trials

Todd Neale

February 06, 2018

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Daily News

Prolonged DAPT Does Not Increase Mortality, Cancer Risk: More Evidence

L.A. McKeown

January 12, 2018

Advertisement

TCTMD’s Top 10 Most Popular Stories for November 2018

Patients With Schizophrenia Reap Gains From CV Meds After MI

TCTMD’s Top 10 Most Popular Stories for September 2018

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Alirocumab Price Slashed in Deal With Express Scripts

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

‘High Index of Suspicion’ First Step in Successful Management of SCAD

Compliance With Preventive Drugs After CABG, PCI Found Lacking in Clinical Trials

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Prolonged DAPT Does Not Increase Mortality, Cancer Risk: More Evidence

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content